Human-Derived
Hanheal Exosome Rejuvenating
Premium human-derived exosome for skin hydration, texture, radiance and elasticity in clinical aesthetic protocols.
HydrationRadiance
View Product Human-Derived Skin Rejuvenation PDRN Hybrid Advanced Formula
PDRN + Exosome Hybrid
A dual-technology Korean aesthetic formulation combining PDRN (polydeoxyribonucleotide) polynucleotide science with human-derived exosomes. This hybrid approach is designed to support comprehensive skin restoration — addressing texture, tone, hydration, and overall skin quality — by leveraging two complementary biological pathways within a single professional product.
PDRN Technology Exosome Signalling Skin Restoration Dual-Active Texture & Tone
Product Overview
Understanding the PDRN + Exosome Hybrid
The PDRN + Exosome Hybrid represents a second-generation approach to Korean professional aesthetic bioactives — combining two well-researched categories within a single formulation. PDRN (polydeoxyribonucleotide), derived from salmon DNA, has an established record in the Korean and European aesthetic literature for tissue support and skin quality applications. Human-derived exosomes contribute a growth factor and cellular signalling payload with emerging supporting evidence in skin rejuvenation contexts.
The hybrid rationale is based on complementary biological activity: PDRN is associated with adenosine receptor pathways and tissue support functions, while exosomes act as cellular messengers delivering growth factors, miRNA, and signalling proteins. Combining both within a single injectable formulation is intended to address multiple dimensions of skin quality simultaneously.
This product category reflects the direction of advanced Korean aesthetic biotech — moving from single-active formulations toward combination technologies designed to deliver broader clinical utility per treatment session.
Important Note: The PDRN + Exosome Hybrid is a professional aesthetic product — not a pharmaceutical or medicinal drug. Neither PDRN nor exosome preparations have received FDA drug approval for skin rejuvenation indications. Evidence is preliminary and evolving. For professional use only.
Dual-Technology Profile
Two Active Systems, One Formulation
PDRN (Polydeoxyribonucleotide)
PDRN is a high-molecular-weight polynucleotide derived from salmon sperm DNA. It has a relatively well-developed evidence base in aesthetic medicine — particularly in the Korean and Italian literature — for tissue support, wound-healing contexts, and skin quality applications including hydration and texture.
Its proposed mechanism involves adenosine A2A receptor stimulation, which is associated with tissue support pathways. PDRN is a distinct, established active with a longer clinical track record than exosomes.
Human-Derived Exosomes
Human-derived exosomes — extracellular vesicles from stem cell conditioned media — contribute a signalling payload including growth factors (EGF, FGF, VEGF, TGF-β and others), miRNA species, and bioactive lipids with emerging supporting evidence for skin quality applications.
Their inclusion in a hybrid formulation represents the next evolution beyond PDRN-only preparations — adding a cellular communication layer with a broader signalling profile.
Clinical Context
Where PDRN + Exosome Hybrid Fits
Post-Procedure Recovery Support
PDRN's established tissue support profile — combined with exosome signalling — makes the hybrid particularly relevant in post-procedure aesthetic contexts where skin quality and comfort are the clinical priority.
Skin Quality Improvement Programmes
For clinic programmes targeting comprehensive skin quality — texture, tone, hydration, and overall complexion — the dual-active approach offers practitioners a broad-spectrum tool within a single injectable formulation.
Advanced Rejuvenation Protocols
Positioned within advanced Korean aesthetic programmes — particularly relevant where clinicians want to progress beyond single-active skin boosters and offer clients next-generation multi-active technology.
Scientific Transparency: PDRN has a longer clinical research history than exosome preparations. The combination of PDRN and exosomes in hybrid formulations is a relatively recent development; independent large-scale clinical trials evaluating combined PDRN+exosome preparations specifically are limited. Evidence is emerging. Review our Science & Evidence page →
Formulation Notes
Active Ingredient Summary
| Active | Origin | Proposed Skin Benefit | Evidence Level |
|---|---|---|---|
| PDRN | Salmon DNA-derived polynucleotide | Tissue support, hydration, texture improvement | Moderate (aesthetic literature) |
| Human Exosomes | Stem cell conditioned media | Cellular signalling, growth factor delivery, skin quality | Emerging / preliminary |
| Growth Factors | Exosome-carried (EGF, FGF, TGF-β) | Skin renewal support, barrier, firmness | Emerging / preliminary |
| Carrier / Excipients | Physiological buffer, stabilisers | Formulation stability and delivery support | Established excipients |
Full formulation specifications and batch characterisation data available to verified professional buyers upon request.
Related Products
Explore the Full Human-Derived Range
Human-Derived
ASCE+ SRLV
ASCE+ range human-derived exosome for visible skin rejuvenation, pore appearance, and firmness support.
ASCE+Firmness
View Product Human-Derived
Exosome Skin Booster
High-concentration human-derived exosome injectable booster for intensive hydration and skin quality enhancement.
InjectableIntensive
View Product Frequently Asked
PDRN + Exosome Hybrid Questions
What is the advantage of combining PDRN with exosomes?
PDRN and exosomes are proposed to act through distinct but complementary biological pathways. PDRN (polydeoxyribonucleotide) is associated with adenosine receptor activity and has a relatively established evidence base in aesthetic medicine for tissue support and skin quality. Exosomes contribute a broader cellular signalling payload — growth factors, miRNA, and bioactive lipids — with emerging evidence in skin rejuvenation. Combining both within a single formulation aims to deliver a broader spectrum of biological activity than either active alone, addressing multiple dimensions of skin quality per treatment session. This remains an area of active investigation, not established clinical consensus.
Is PDRN from salmon DNA safe for use in aesthetic treatments?
PDRN derived from salmon (Oncorhynchus mykiss) DNA has been used in aesthetic and medical contexts — particularly in Korea and Italy — for a number of years with a generally well-tolerated safety profile reported in the published literature. Allergy to fish or seafood may be a relevant consideration; full contraindication assessment by the treating practitioner prior to use is essential. Refer to manufacturer product literature for the full safety profile.
How does the PDRN + Exosome Hybrid compare to pure exosome products?
Pure exosome products — such as Hanheal or ASCE+ SRLV — deliver a concentrated exosome payload as the sole primary active. The PDRN + Exosome Hybrid adds PDRN's polynucleotide contribution alongside the exosome component, creating a dual-active formulation. Practitioners may choose between these based on clinical indication, patient profile, treatment programme context, and their own clinical experience with each product category. Neither approach is universally superior; product selection should be guided by individual clinical assessment.
What treatment areas is this product appropriate for?
The PDRN + Exosome Hybrid is formulated for professional facial skin rejuvenation protocols. Specific treatment area guidelines — including face, neck, décolletage, and periorbital considerations — are provided in the manufacturer's clinical protocol documentation. Anatomical area suitability should be assessed on a case-by-case basis by the treating clinician.
Advance Your Clinic's Protocols
The PDRN + Exosome Hybrid is available through verified professional wholesale channels. Request technical specifications, pricing, and clinical protocol support.